版本:
中国

BRIEF-Orexigen Therapeutics reports Q4 loss per share $1.69

March 28 Orexigen Therapeutics Inc -

* Orexigen Therapeutics reports financial results for the fourth quarter and year ended December 31, 2016

* Q4 loss per share $1.69

* Q4 revenue $13.9 million versus $4.9 million

* According to IMS Health, 140,755 total prescriptions of contrave were filled in q4 of 2016 versus 185,944 total prescriptions filled in q4 of 2015 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐